Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
+0.37 (0.80%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.00 - 47.15
52 week 31.38 - 80.11
Open 45.90
Vol / Avg. 642,690.00/889,817.00
Mkt cap 4.04B
P/E     -
Div/yield     -
EPS -4.79
Shares 86.01M
Beta 2.69
Inst. own 95%
Feb 9, 2017
Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated)
Jan 9, 2017
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2017
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 16, 2016
Alnylam Pharmaceuticals Inc R&D Day
Dec 4, 2016
Alnylam Pharmaceuticals to Discuss Clinical Results at ASH
Nov 30, 2016
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -647.04% -869.63%
Operating margin -661.36% -900.33%
EBITD margin - -868.25%
Return on average assets -35.17% -30.96%
Return on average equity -46.81% -37.54%
Employees 514 -
CDP Score - -


300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Michael P. Mason Chief Financial Officer, Principal Accounting Officer, Vice President, Treasurer
Age: 42
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters